Outcomes of locally advanced breast cancer patients with ≥10 positive axillary lymph nodes

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Koca, Emre ^a   Kuzan, Taha Y ^a   Dizdar, Omer ^b   Babacan, Taner ^a   Sahin, Ilyas ^a   Ararat, Erhan ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Outcome; Stage pN3a; Treatment

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE RATIO; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PERINEURAL INVASION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY; YOUNG ADULT; ADJUVANT THERAPY; AXILLA; BREAST NEOPLASMS; GENETICS; LYMPH NODE; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; BREAST TUMOR;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878250576     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0615-7     Document Type: Article

References (26)

1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391-401.
2. Glass AG, Lacey JV Jr, Carreon JD, et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99:1152-61.
3. Newman LA. Epidemiology of locally advanced breast cancer. Semin Radiat Oncol. 2009;19:195-203.
4. Cianfrocca M, Goldstein LC. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606-16.
5. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. SurgClin North Am. 2003;83:803-19.
6. Basaran G, Devrim C, Caglar HB, Gulluoglu B, Kaya H, Seber S, Korkmaz T, Telli F, Kocak M, Dane F, Yumuk FP, Turhal SN. Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years? Med Oncol. 2011;28:726-32.
7. Lee JS, Kim SI, Choi SY, Park HS, Lee JS, Park S, Koo J, Park BW, Lee KS. Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes. Int J Clin Oncol. 2011;16:473-81.
8. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
9. Montero AJ, Rouzier R, Lluch A, et al. The natural history of breast carcinoma in patients with [or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer. 2005;104:229-35.
10. Duraker N, Caynak ZC, Bati B. Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma? Ann SurgOncol. 2008;15:430-7.
11. Buzdar AU, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-b containing adjuvant therapy. Cancer. 1992;69(2):448-52.
12. Walker MS, et al. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995;169:575-9.
13. Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M. German breast cancer study group. Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001;37:1123-31.
14. Ito M, Moriya T, Ishida T, et al. Significance of pathological evaluation for lymphatic vessel invasion in invasive breastcancer. Breast Cancer. 2007;14:381-7.
15. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240:306-12.
16. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006;24:2910-6.
17. Schiffman SC, McMasters KM, Scoggins CR, Martin RC, Chagpar AB. Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients. J Am Coll Surg. 2011;213:45-52.
18. van der Wal BC, Butzelaar RM, van der Meij S, Boermeester MA. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol. 2002;28:481-9.
19. Zhu C, Wu XZ. Proposal of new classification for stage III breast cancer on the number and ratio of metastatic lymph nodes. J Surg Oncol. 2012;106:696-702.
20. Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be considered for incorporation into staging for breast cancer. Ann Surg Oncol. 2011;18:3143-8.
21. Vinh-Hung V, Verkooijen HM, Fioretta G, Neyroud-Caspar I, Rapiti E, Vlastos G, Deglise C, Usel M, Lutz JM, Bouchardy C. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062-8.
22. Geara FB, Nasr E, Tucker SL, Charafeddine M, Dabaja B, Eid T, Abbas J, Salem Z, Shamseddine A, Issa P, El Saghir N. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome. Int J Radiat Oncol Biol Phys. 2007;68:364-9.
23. Petrelli F, Borgonovo K, Barni S. The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature. Eur J Surg Oncol. 2011;37:836-47.
24. Schneider DF, Chen H, Sippel RS. Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol. 2012 Dec 23. [Epub ahead of print].
25. John BJ, Naik P, Ironside A, Davidson BR, Fusai G, Gillmore R, Watkins J, Rahman SH. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB (Oxford). 2013;. doi:10.1111/hpb.12019.
26. Qiu C, Dong W, Su B, Liu Q, Du J. The prognostic value of ratiobased lymph node staging in resected non-small-cell lung cancer. J Thorac Oncol. 2013;8:429-35.